CyLip-20
CyLip-20 is a cyclic lipopeptide antimicrobial peptide that targets Gram-positive and Gram-negative bacteria. CyLip-20 exhibits low hemolytic activity and mild in vivo toxicity. CyLip-20 disrupts the integrity of bacterial outer membrane, inner membrane and cytoplasmic membrane by binding to bacterial lipopolysaccharide (LPS), triggering membrane permeabilization, depolarization and leakage of intracellular contents, and inhibits bacterial biofilm formation. In animal models, CyLip-20 reduces the bacterial load in skin wounds of mice infected with MRSA, promotes wound healing, decreases the levels of inflammatory cytokines and reduces inflammatory cell infiltration. CyLip-20 can be used in research related to MRSA skin wound infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C78H117N19O14
- Masse moléculaire:1544.88
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
CyLip-20 (4-32 μM; 18-24 h) exhibits broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria, including Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853, with a GMall of 5.19 μM[1].
CyLip-20 (10 mM; 0-48 h) remains highly stable in mouse serum with a half-life exceeding 48 h[1].
CyLip-20 (1 mM; incubated with proteases for 6 h) shows high stability against trypsin and chymotrypsin (0.02-200 μg/mL), and retains antimicrobial activity in both cases[1].
CyLip-20 (1/2×MIC-4×MIC; 24 h) exerts a concentration-dependent inhibitory effect on biofilm formation by Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), and Pseudomonas aeruginosa (P. aeruginosa)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:S. aureus ATCC 25923, B. subtilis ATCC 23857, S. epidermidis ATCC 12228, E. faecalis ATCC 29212, E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, A. baumannii ATCC 19606
-
Concentration:MIC
-
Incubation Time:24 h
-
Result:Showed MIC values of 4 μM for S. aureus ATCC 25923, B. subtilis ATCC 23857, S. epidermidis ATCC 12228, E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, A. baumannii ATCC 19606, and showed a MIC value of 32 μM for E. faecalis ATCC 29212.
Inhibited the biofilm formation in a concentration-dependent manner against S. aureus, E. coli, and P. aeruginosa.
CyLip-20 (30-130 mg/kg; i.p.; single dose) has an LD50 of 62.52 mg/kg in male BALB/C mice, showing lower in vivo toxicity than Polymyxin B (HY-149179)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MRSA skin wound infection model in BALB/C mouse (male, 6-8 weeks old, 20 ± 2 g)[1]
-
Dosage:2 mg/mL; 10 μL
-
Administration:topical; 6 times at 1 h intervals; observed the wound healing at days 12.
-
Result:Reduced MRSA bacterial load at the wound site.
Significantly promoted wound healing, with wound area smaller than model and vancomycin groups by day 4, scabs almost fell off by day 6, wounds almost completely healed by day 8.
Reduced serum TNF-α levels.
Rendered skin tissue structure closest to healthy control with no obvious cell swelling, necrosis, or abnormal proliferation.
Reduced macrophage and neutrophil infiltration at the wound site
Chemical Information
-
Masse moléculaire 1544.88
-
Formule C78H117N19O14
-
Sequence
C8-{Dab}-{Dab}-Trp-{d-Tyr}-cyclo(Lys-{Dab}-{Dab}-Trp-{d-Leu}-{d-Leu}-Glu)
-
Sequence Shortening
C8-{Dab}-{Dab}-W-{d-Tyr}-cyclo(K-{Dab}-{Dab}-W-{d-Leu}-{d-Leu}-E)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)